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Abstract: Immune responses to expressed foreign transgenes continue to hamper progress of gene therapy development. 
Translated foreign proteins with intracellular location are generally less accessible to the immune system, nevertheless 
they can be presented to the immune system through both MHC Class I and Class II pathways. When the foreign protein 
luciferase was expressed following intramuscular delivery of plasmid DNA in outbred mice, expression rapidly declined 
over 4 weeks. Through modifications to the expression plasmid and the luciferase transgene we examined the effect of de-
targeting expression away from antigen-presenting cells (APCs), targeting expression to skeletal muscle and fusion with 
glycine-alanine repeats (GAr) that block MHC-Class I presentation on the duration of luciferase expression. De-targeting 
expression from APCs with miR142-3p target sequences incorporated into the luciferase 3’UTR reduced the humoral im-
mune response to both native and luciferase modified with a short GAr sequence but did not prolong the duration of ex-
pression. When a skeletal muscle specific promoter was combined with the miR target sequences the humoral immune re-
sponse was dampened and luciferase expression persisted at higher levels for longer. Interestingly, fusion of luciferase 
with a longer GAr sequence promoted the decline in luciferase expression and increased the humoral immune response to 
luciferase. These studies demonstrate that expression elements and transgene modifications can alter the duration of trans-
gene expression but other factors will need to overcome before foreign transgenes expressed in skeletal muscle are immu-
nologically silent. 
Keywords: Gene therapy, luciferase, microRNA, plasmid DNA, skeletal muscle, tissue-specific promoter, transgene immuno-
genicity. 
INTRODUCTION 
Gene therapy has the potential to revolutionise the way 
that diseases are treated. Genetic diseases can be reversed 
by delivery of the correct gene copy or a correction can be 
made to an existing gene. In other diseases, gene therapy 
could be utilised for the long-term delivery of secreted or 
intracellular therapeutic molecules. Despite the huge poten-
tial, progress with gene therapy has been slow. Initial clini-
cal success was achieved in patients who had a compro-
mised immune system (e.g. X-SCID) and more recently 
gene therapy has been performed in immune privileged 
sites (e.g. Leber congenital amaurosis [1]). Gene therapy 
approaches that involve the expression of ‘foreign’ or any 
immunogenic protein, for which the recipient immune sys-
tem has not been tolerised, will likely be hampered in an 
immunocompetent patient. The most pertinent example is 
expression of a correct gene in a genetic disease where 
clearly there is no tolerance to the correct protein. In other 
situations, such as pharmacologically regulated gene ther-
apy [2, 3], expression of an immunogenic transactivator is  
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often necessary [4, 5]. Therefore, an important hurdle for 
the wider application and success of gene therapy is to de-
velop ways to avoid rejection of ‘foreign’ transgenes. 
Plasmid DNA has advantages as a gene therapy vector in 
terms of immunology because it is devoid of protein compo-
nents and does not typically elicit anti-vector immune re-
sponses, but for gene delivery it is relatively poor because it 
does not efficiently enter cells. Transfection is observed follow-
ing plasmid injection in skeletal muscle [6] which can result in 
long-term gene expression in experimental models, but in clini-
cal trials it has been less efficient with low level, transient (less 
than 2 weeks) expression observed [7]. The efficiency of trans-
fection of skeletal muscle in experimental models can be en-
hanced by physical methods such as electroporation (EP) [8] or 
hydrodynamic delivery through the vasculature [9]. In these 
studies, long-term expression of proteins occurs because trans-
fected myocytes are terminally differentiated, non-dividing cells 
so episomal plasmid DNA is not rapidly lost.  
Immune responses to foreign transgenes (antigen: Ag) 
expressed in muscle develop because the Ag in myoblasts 
activated with IFN can be presented on expressed MHC 
Class I and II [10, 11] and are the target for Ag-specific cyto-
toxic CD8+cells which are observed within 2 weeks of DNA 
delivery [12]. Transfected resident APCs [13, 14] will 
present intracellular transgenes via their MHC class I leading 
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to activation of cytotoxic CD8+ T cells. Extracellular Ag 
(released during cell death) can be taken up by recruited 
macrophages {McMahon, 1998 #729} and APCs by pinocy-
tosis and presented by MHC Class II to activate CD4+ T 
helper cells which play a direct role in the clearance of trans-
fected cells through MHC Class II interaction and the 
Fas/FasL signalling pathway [15, 16]. When there are high 
concentrations of extracellular Ag ‘cross-presentation’ 
through MHC Class I to CD8 cells by a route dependent on 
mannose receptor mediated endocytosis also occurs [17].  
Strategies to avoid immunogenicity have been aimed at 
preventing APCs from processing and presenting Ag via 
MHC Class I in order to inhibit CD8 priming. In one ap-
proach termed ‘de-targeting’, transgene expression in APCs is 
averted through the use of a tissue specific promoter in com-
bination with micro RNA (miR) target sequences in the 
3’UTR. When EGFP was expressed from a liver specific al-
bumin promoter and miR 142-3p target sequences were in-
cluded in the 3’UTR (to prevent transgene expression in 
APCs), EGFP immunogenicity was avoided [18]. A subse-
quent study has shown that this de-targeting strategy results 
in the formation of Ag-specific regulatory T cells which pro-
mote immunological tolerance [19]. There are also viral pro-
teins that are able to evade immune detection such as EBNA-
1, an Epstein Barr Virus nuclear protein, which has been 
shown to persist in infected B cells without formation of cyto-
toxic CD8 cells. Full length EBNA-1 is 641 amino acid (aa) 
long and contains a glycine-alanine repeat (GAr) sequence 
composed of over 230 aa. This GAr sequence has several 
proposed effects which contribute to evading the immune 
system, these include inhibition of proteasomal processing 
[20] which could be through destabilising the interaction of 
ubiquinated substrate with the proteasome [21]. Other attrib-
utes include ribosomal effects resulting in self inhibition of 
synthesis [22] potentially due to the purine rich mRNA se-
quence [23], as well as delayed assembly of the initiation 
complex on its own mRNA [24]. The consequence of these 
properties is that EBNA-1 is expressed at low levels and is 
not efficiently processed for MHC Class I presentation. Im-
portantly, some of these effects of the GAr sequence have 
also been replicated with shorter GAr sequences (as short as 7 
aa) [25]. There has been some success in utilising either the 
full length GAr [26] or a shorter GAr sequence (24 aa, [27]) 
to prolong foreign transgene expression in vivo.  
In this study we have utilised the reporter gene luciferase as 
a prototype foreign intracellular transgene. Through the use of 
bioluminescent imaging we are able to monitor persistence of 
luciferase expression. The decline in luciferase expression in 
outbred mice is associated with development of a T cell re-
sponse and antibodies [28]. Here we examine alterations to the 
vector so that luciferase expression is either targeted to myo-
cytes with a specific promoter, or away from APCs through the 
use of miR 142-3p target sequences in the luciferase 3’UTR and 
the influence of fused GAr elements on the duration of lu-
ciferase expression and humoral immune response. 
MATERIALS & METHODS 
Cells, Bacteria and Chemicals 
Plasmid DNA was propagated in DH5- Escherichia coli 
and was purified using a standard Plasmid Mega Kit (Qiagen 
Ltd., Crawley, West Sussex, UK) when DNA was prepared 
for in vivo application, the EndoFree™ Plasmid Mega Kit 
(Qiagen Ltd.) was used. The mouse myoblast cell line C2C12 
(ECACC no. 91031101), human embryonic kidney epithelial 
cell line 293T, and human monocytic cell line U937 (ECACC 
no. 85011440) were grown at 10% CO2 in Dulbecco’s modi-
fied Eagle’s medium (Cambrex Bio Science Verviers S.p.r.l., 
Verviers, Belgium) supplemented with 10% foetal bovine 
serum (Invitrogen Corporation, Carlsbad, CA, USA), glu-
tamine (2 mM) (Cambrex Bio Science Verviers S.p.r.l.), peni-
cillin (100 U/ml) (Cambrex Bio Science), and streptomycin 
(100 μg/ml) (Cambrex Bio Science). Unless stated otherwise, 
chemical reagents were purchased from Sigma-Aldrich (St. 
Louis, MO, USA) and DNA-modifying enzymes from New 
England BiolabsUk Ltd (Hitchin, Herts, UK). 
DNA Constructs 
The vector pcLuc+ that expresses cytoplasmic luciferase 
from the CMV promoter has been described previously [29]. 
To ensure that only luciferase was expressed from this vec-
tor, expression of the neomycin resistance gene (present in 
the original pcDNA 3 vector), was prevented by removing 
part of the promoter and start codon of NeoR by digestion 
with the restriction enzymes SexAI and Tth III generating 
the plasmid pcLuc+/-NeoR. Two repeats of the hsa-miR-
142-3p target with exact complimentary sequence (in bold) 
were incorporated into the luciferase 3’UTR using the fol-
lowing oligonucleotides: 5’-CTAGTCCATAAAGTAGGA 
AACACTACACGATTCCATAAAGTAGGAAACACTA 
CATCTAGAATTCGGGCC-3’ and 5’-CGAATTCTAGA 
TGTAGTGTTTCCTACTTTATGGAATCGTGTAGTG 
TTTCCTACTTTATGGA-3’ which were annealed over-
night and inserted into pcLuc+/-NeoR linearised with XbaI 
and ApaI. The resulting plasmid pcLuc+/miR2T/-NeoR was 
digested with XbaI and ApaI and additional annealed oli-
gonucleotides (miR 2T) were inserted to generate the 
pcLuc+/miR4T/-NeoR.  
The synthetic muscle specific promoter c5-12 [30] (gift 
from ADViSYS, Inc., Texas, USA) was cloned into firefly 
luciferase containing vectors pcLuc+/-NeoR and 
pcLuc+miR4T/-NeoR by digesting them with NruI and 
BamHI to remove the CMV promoter. The pAV0243 plas-
mid (containing the c5-12 promoter) was digested with SacI, 
blunted with Klenow and digested with BamHI to isolate the 
c5-12 muscle specific promoter which was cloned into the 
prepared vectors. The resulting plasmids were called c5-
12Luc+/-NeoR and c5-12Luc+miR4T/-NeoR. 
To insert glycine-alanine repeats in the C-terminal end of 
luciferase protein, luciferase containing constructs had to be 
modified to generate plasmids with an Nhe1 restriction site 
just after the start codon. Both Luc+/-NeoR and Luc+miR4T/-
NeoR were amplified by polymerase chain reaction using the 
following primers: Luc+ 5’ EcoRI-NheI: 5’-ccgGAATTC 
accatgGCTAGCgaagacgccaaaaacata-3’ and pcDNA3 Apa1: 
5’-gacactatagaataGGGCCC-3’. The PCR products were 
cloned into the TA cloning vector pCR2.1 (Invitrogen Ltd, 
Paisley, UK). The pCR-Luc+/NheI and pCR-Luc+/ 
miR4T/NheI vectors were then digested with EcoR1 and 
ApaI, purified and inserted into the pcDNA3/-NeoR vector 
that was previously cut with EcoR1 and ApaI. GAr30 contain-
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ing constructs were generated by annealing the following oli-
gonucleotides before ligation in to these vectors digested with 
EcoRI and NheI: Forward primer (1) 5’ AATTC ACC ATG 
TCT AGA GCT GGA GCA GGC GGT GGA GCA GGT 
GCT GGA GGT GCA G and Reverse primer (1) 5’ TCC 
ACC TGC ACC TCC AGC ACC TGC TCC ACC GCC TGC 
TCC AGC TCT AGA CAT GGT G; Forward primer (2) 5’ 
GT GGA GCA GGC GGT GCA GGA GCA GGT GGT GCA 
GGT GCT GGA GGT GGA GCA GGT A; Reverse primer 
(2) 5’ C TAGT ACC TGC TCC ACC TCC AGC ACC TGC 
ACC ACC TGC TCC TGC ACC GCC TGC. 
A fragment from EBNA-1 consisting of the first 1260 
nucleotides, including the sequence encoding the full length 
GAr (located between aa 90 and 328) was amplified by PCR 
from pCEP-4 (Invitrogen Ltd.): Forward primer 5’ TCG 
GAA TTC ACC ATG TCT AGA GAG GGG CCA GGT 
ACA and Reverse primer 5’ GG ACT AGT GCC ACC TTC 
TTG GTG GTA. PCR products were cloned into the TA 
cloning vector pCR2.1. The newly generated pCR-E1260 
vector was then digested with EcoRI and SpeI to excise the 
first 1260 bp of EBNA-1, purified and subcloned into the 
pcLuc+/-NeoR and pcLuc+/miR4T/-NeoR vectors linearised 
by EcoRI and NheI digestions producing the vectors pcLuc+/ 
GAr/-NeoR and pcLuc+/GAr/miR4T/-NeoR, respectively. 
The plasmid pcLuc+/GAr30/miR4T/-NeoR was gener-
ated by digesting pcLuc+/miR4T/-NeoR plasmid with MluI 
and XcmI and discarding the 1534 bp fragment and replacing 
it with the CMV-Luc+GAr30/MluI/XcmI fragment excised 
from the pcLuc+/GAr30/-NeoR plasmid.  
To modify the luciferase gene by adding GAr30 in the 
c5-12 plasmids, the c5-12Luc+/-NeoR and c5-
12Luc+miR4T/-NeoR plasmids were digested with BamHI 
and XcmI removing an 885 bp fragment. The fragment 
Luc+GAr30/BamHI/XcmI excised from pcLuc+GAr30/-
NeoR was then subcloned into the linearised vectors produc-
ing the plasmids c5-12Luc+/GAr30/-NeoR and c5-
12Luc+/GAr30/mir4T/-NeoR. To generate the plasmids c5-
12Luc+/GAr/-NeoR and c5-12Luc+/GAr/miR4T/-NeoR a 
Luc+/GAr/BamHI/NarI fragment was excised from 
pcLuc+/GAr/-NeoR and was subcloned into the c5-12Luc+/-
NeoR and c5-12Luc+miR4T/-NeoR plasmids linearised with 
BamHI and NarI. 
All vectors constructed in this study were validated by 
DNA sequencing and are depicted schematically in Fig. (1a). 
Cell Transfection 
Plasmids were transfected into 293T cells by calcium 
phosphate precipitation or introduced into human monocytic 
U937 cells and mouse myoblastic C2C12 cells using the 
AMAXA Nucleofector® device (Lonza Group Ltd., Basel, 
Switzerland with cell line Nucleofector® Kit C and the rec-
ommended protocol for the cells) and Fugene® 6 (Roche 
Diagnostics Ltd, Burgess Hill, UK), respectively. The plas-
mid pRL-CMV (Promega Corporation, Madison, WI, USA), 
that encodes the renilla luciferase gene, was used as a control 
for transfection efficiency and was introduced to all cells. 
Cells were lysed 24 or 48 hours after transfection and lysates 
were used for dual luciferase assays. Luciferase activity was 
measured with an MLX Microtiter® Plate Luminometer 
(Dynex Technologies, Chantilly, VA, USA). 
 
Fig. (1). Illustration of expression cassettes and luciferase ex-
pression in transfected cells. (a) In the constructs either the ubiq-
uitous CMV (grey) or skeletal muscle specific c5-12 (check) pro-
moters were used to drive expression of luciferase (black) either 
unmodified or with a GAr (white) fusion at the amino terminus. In 
some constructs 142-3p miR target sequences (striped) were incor-
porated in the 3’UTR. (b) Luciferase expression was assessed by 
transient co-transfection of C2C12 cells (1x106) with the construct 
of interest (2 ng) and pRL-CMV (0.2 ng) by nucleofection using the 
Amaxa Nucleofector® device, with luciferase expression assessed 
after 24 hours. Values are the mean of triplicate readings with verti-
cal bars representing SEM and representing a significant (p<0.05) 
difference from pcLuc+ or c5-12-Luc+ in the respective histograms. 
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Western Blot 
Plasmid DNA (20 μg) was transfected into 293T cells 
through calcium phosphate precipitation. Seventy-two hours 
after the transfection cells were washed with cold PBS and 
lysed in RIPA buffer containing a protease inhibitor cocktail 
and sodium orthovanadate. Protein concentration of the 
lysates were determined using the Pierce® BCA protein as-
say kit (Thermo Fisher Scientific Inc.) and equal amounts of 
protein were diluted in Laemmli sample buffer and run on 
SDS-PAGE electrophoresis gels [31] and then transferred 
onto a polyvinylidene difluoride (PVDF) membrane (Amer-
sham International Plc, UK) by electroblotting. Immunoreac-
tive mouse sera were used to detect luciferase protein and a 
secondary antibody for detection of bands was HRP conju-
gated F(ab’)2 goat anti-mouse IgG (Santa Cruz Inc, CA, 
USA). 
PCR Amplification of miRs 
To determine the presence of miRNA 142-3p in different 
cell lines, including U937, C2C12 and HEK 293T cells, the 
small RNA enriched fraction was isolated using the mirVana 
miRNA isolation kit (Applied Biosystems, Warrington, UK). 
Reverse-transcription and polymerase chain reaction (PCR) 
were performed to detect miRNA 142-3p and miRNA 16 
using SBI QuantiMir RT kit.  
In vivo Gene Delivery 
Mice were treated according to approved Home Office 
and institutional guidelines. Outbred 8 to 10 week old male 
NIH Swiss mice (Harlan UK Ltd; Bicester, Oxon, UK) and 
Beige SCID immunodeficient mice, strain 250, from Charles 
River were anaesthetised with isofluorane (isoflurane, Baxter 
Healthcare Ltd., Norfolk, UK) using Boyle’s apparatus 
(Linde AG, Wiesbaden, Germany). The fur covering the left 
anterior tibialis was shaved and the exposed skin was 
sprayed with disinfectant. Endotoxin-free plasmid for injec-
tion was prepared in a solution of 0.9% NaCl at a concentra-
tion of 1166 μg/ml. DNA (30 μl) was administered by intra-
muscular (i.m.) injection at a single site using a TriGrid nee-
dle array (Ichor Medical Systems Inc. San Diego, CA, USA). 
The muscle was then electroporated (four pulses at 220 
V/cm, pulse duration 10 ms, frequency 6 Hz) using a BTX 
Electro Square Porator ECM 830 (Harvard Apparatus) in 
groups of 5 mice. This all-in-one injection and electropora-
tion array has the added advantage that the injection site is 
the same muscle depth in all mice [32]. Plasmid delivery to 
lungs was performed by complexing DNA with jetPEI
TM
 
(Polyplex Transfection, Cedex, France) at a N/P ratio of 10 
and a final glucose concentration of 5%. DNA lipid complex 
formed during 20 minutes incubation at room temperature 
then female Balb/c mice (Harlan UK Ltd; Bicester, Oxon, 
UK) were injected i.v. with 100 μl of complex containing 20 
μg DNA.  
Whole Body Bioluminescent Imaging 
In vivo expression of luciferase was monitored by non-
invasive imaging. Mice were given an i.p. injection of 200 μl 
of luciferin K+ salt (30 mg/ml; Promega Corp). Mice were 
then anaesthetised with isofluorane. Anaesthetised mice were 
then photographed (0.2-second exposure) and imaged for 
light emission between 1 second and five minutes on high 
sensitivity with the IVIS
®
 100 series (Caliper Life Sciences 
Inc, Hopkinton, MA, USA). Luciferase images were overlaid 
on the photograph, and emission of light was quantified as 
photons per steradian per square centimetre using Living 
Image
®
 software version 3 (Caliper Life Sciences Inc.) from 
a defined region of interest around the anterior tibialis mus-
cle and from control areas of the same size on the abdomen 
of the same mouse. 
Anti-Luciferase Antibody Measurement 
Levels of anti-luciferase activity in sera were measured 
by Elisa. Microtitre plates were coated overnight at 4°C 
with 100 μl of recombinant luciferase (2 μg/ml Roche Di-
agnostics Ltd) prepared in bicarbonate buffer (pH 9.5). 
Plates were washed with PBS and then blocked with 2% 
marvel solution in PBS for 1 hour at room temperature. 
Plates were again washed with PBS/Tween (0.05%) and 
then day 28 serum (diluted from 1:10 up to 1:1x10
8
 with 
PBS Tween) was incubated for 3 hours at room tempera-
ture. After washing with PBS/Tween, bound antibody was 
detected using HRP conjugated sheep anti-mouse IgG di-
luted 1:1000 (OBT 1508P; AbDSerotec, Kidlington, UK). 
After 1 hour the signal was detected using the TMB mi-
crowell substrate system (Kirkegaard and Perry Laborato-
ries Inc., Gaithersburg, MD, USA) and the reaction stopped 
by addition of 4M sulphuric acid (100 μl). Absorbance 
measurements were performed at 450 nm using a Tecan-
GENios microplate reader (Tecan Group Ltd; Männedorf, 
Switzerland) with Magellan 4 software. Absorbance read-
ings were compared against a standard generated with a 
rabbit anti-luciferase IgG fraction of sera which was de-
tected with a secondary HRP conjugated sheep anti-rabbit 
IgG diluted 1:1000 (Star 54; AbDSerotec). 
Splenocyte Stimulation 
Spleens were collected from mice at the end of the ex-
periment and cells were dispersed using a nylon cell strainer 
(70 μm; Becton Dickinson Labware, FranklinLakes, NJ, 
USA). Cell suspensions were centrifuged and contaminating 
erythrocytes removed by treatment with red blood cell lysing 
buffer. Cells were then resuspended in complete DMEM and 
seeded at 3x10
6
/well in 96-well microtitre plates and were 
stimulated with luciferase (2 μg/ml) or ConA (3 μg/ml) for 
48 hours, after which supernatants were collected and stored 
at –80°C until measurement of IL-2 by ELISA. IL-2 levels 
from Con A and luciferase stimulated cells were adjusted for 
levels produced by non-stimulated cells. 
Statistical Methods 
Significant differences were calculated using the Stu-
dent’s t test (Microsoft Excel 97) and area under the curve 
was calculated using GraphPad Prism software (GraphPad 
Software Inc. version 4). 
RESULTS 
Luciferase Expression Vectors 
The luciferase expression plasmids constructed in this 
study were co-transfected into C2C12 cells by nucleofection 
and were all shown to express luciferase (Fig. 1b). From the 
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results it can be seen that higher levels of expression were 
observed with the CMV promoter compared to the c5-12 
promoter, reflecting the weak activity of the c5-12 promoter 
in the undifferentiated C2C12 cells compared to the CMV 
promoter [30]. The results also show that the GAr modifica-
tions had a significant effect on levels of luciferase expres-
sion. The GAr30 domain increased expression levels of lu-
ciferase from both promoters whilst the full length GAr 
caused a dramatic reduction in expression levels. By con-
trast, addition of the miR 142-3p target sequence only caused 
a small decrease in luciferase expression. The relative ex-
pression of the constructs in vivo is displayed in Table 1 as 
area under the curve (AUC) and absolute values, interest-
ingly the different elements have a similar effect on expres-
sion in vivo as they do in vitro.  
Longevity of Luciferase Expression in the Absence of an 
Adaptive Immune Response 
When plasmid encoding luciferase was delivered by IM 
injection in combination with EP to Beige SCID mice, there 
was a significant decrease in luciferase expression within the 
first two weeks of plasmid delivery before stable expression 
was maintained at approximately 50% of the day 7 maxi-
mum (Figs. 2a and b). Due to the absence of an adaptive 
immune system in SCID mice this decrease can be attributed 
to the innate immune response (with reduced NK cell activ-
ity), tissue remodelling following electroporation and pro-
moter silencing. It provides an indication of the gene expres-
sion kinetics which could be achieved if the adaptive im-
mune response can be evaded. 
Outbred Mice Provide a Stringent Model to Monitor Du-
ration of Luciferase Expression 
As shown in Fig. (3a), luciferase expression in immuno-
competent mice that received pcLuc+/-NeoR was dramati-
cally reduced within 28 days of delivery. In these mice there is 
a rapid reduction in luciferase expression which after 4 weeks 
is reduced by 93% compared to the day 7 peak, and is associ-
ated with production of antibodies (Fig. 3b) and reactive T 
cells (Supplementary Fig. 6bc). Table 1 provides summary 
data on the production of anti-luciferase antibodies in these 
mice. 
Skeletal Muscle Targeted Transgene Expression 
The synthetic muscle-specific promoter c5-12 has previ-
ously been shown to selectively target expression to skeletal 
muscle in vivo and to have equivalent strength to the CMV 
promoter [30]. The tissue specific characteristic of c5-12 was 
confirmed in this study by in vivo transfection methods for 
skeletal muscle and mouse lung. Luciferase expression levels 
from the c5-12 promoter (6.65±0.63x105 photons/steradians/ 
cm2) were approximately half that seen for the CMV pro-
moter (1.49±0.34x106 photons/steradians/cm2) in skeletal 
muscle on day 7 (Fig. 4a), but in lung transfected by Jet-
PEI™ delivery of plasmid DNA (20 μg), expression of lu-
ciferase was only observed with pcLuc+ (Fig. 4b). When 
luciferase expression was examined in outbred NIH Swiss 
mice the kinetics profile was similar for the c5-12 
(AUC=6.83) and CMV (AUC=5.99) promoters (Figs. 4c and 
d). However, targeting expression to skeletal muscle signifi-
cantly (p0.05) reduced the level of anti-luciferase antibody 
production at day 28 (Table 1, Fig. 9b). 
Table 1. Summarised data for the different treatment groups. 
Vector 
Protein  
Expressed 
Group Size
a
 
Day 7
b
  
Luciferase 
AUC/s
c  
(x10
6
) 
Anti-Luc-Ab
d
 
(x10
6
) 
Anti-Luc Ab ÷ 
AUC/s
e
 
pcLuc+/-NeoR Luc 5 (9) 885,980 5.99 52 10.18 
pcLuc+/4T/-NeoR Luc 5 (8) 508,410 3.07 2.2 0.81 
pcLuc+/GAr30/-NeoR GAr30-Luc 5 2,134,044 10.7 56.6 5.22 
pcLuc+/GAr30/4T/-NeoR GAr30-Luc 5 776,300 6.96 9.7 1.59 
pcLuc+/GAr/-NeoR GAr-Luc 5 654.7 0.00341 7.4 2869.86 
pcLuc+/GAr/4T/-NeoR GAr-Luc 5 102,824 0.499 9.1 20.09 
c5-12Luc+/-NeoR Luc 4 (7) 675,214 6.83 18.3 3.35 
c5-12Luc+/4T/-NeoR Luc 5 (9) 743,600 6.62 13.1 1.96 
c5-12Luc+/GAr30/-NeoR GAr30-Luc 5 1,759,869 10.8 42.9 5.02 
c5-12Luc+/GAr30/4T/-NeoR GAr30-Luc 5 655,866 7.25 18.2 4.54 
c5-12Luc+/GAr/-NeoR GAr-Luc 5 357,090 1.70 16.6 10.98 
c5-12Luc+/GAr/4T/-NeoR GAr-Luc 5 302,918 1.04 10.6 16.87 
a Group size is number of mice with parallel expression and antibody measurements, Values in brackets are total number of mice used for expression data. 
b Represents the actual luciferase activity at day 7 in steradians/cm2/sec 
c Area under the curve (AUC) calculated from actual luciferase activity values up to day 28. Readings are adjusted to values per second of imaging. 
d Anti-Luc Ab (IgG) in day 28 sera determined by Elisa and is a mean value for the group expressed as pg/ml 
e Anti-Luc Ab/AUC/s: This value is calculated by dividing the luciferase antibody level by the AUC value, which gives a ratio of antibody production relative to the luciferase activ-
ity. 
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Fig. (2). Luciferase expression in SCID mice. The constitutively 
encoding luciferase plasmid pcLuc+/-NeoR (35 μg) was delivered 
by i.m. injection in combination with EP and expression of lu-
ciferase was monitored by bioluminescent imaging at weekly inter-
vals until day 28. Bioluminescent images for day 7 to 28 are de-
picted in (a). Luciferase activity in these images was quantified 
using living-image® software. The reduction in luciferase expres-
sion from the day 7 peak is illustrated in (b) as the fraction of re-
maining expression, with mean values plotted +/- SEM. 
 
APC De-Targeted Transgene Expression 
The target sequence for miR-142-3p should prevent ex-
pression of luciferase in haematopoietic cells, including 
APCs. We cloned two and four copies of the target sequence 
for miR-142-3p into the 3’UTR of pcLuc+. Endogenous 
miRNA can be detected in cells of haematopoietic lineage - 
monocytic U937 cells and Ramos B cell line, but not in 
myoblastic C2C12 cells nor in human embryonic kidney 
293T cells (Fig. 5a). The specificity of expression of the 
different constructs generated was initially tested in vitro. 
C2C12 and 293T cells express luciferase after being trans-
fected with luciferase containing plasmids with or without 
the 142-3p miR target sequences (Fig. 5b). This expression 
of luciferase was abrogated in cells transfected with 
pcLuc+/miR2T or miR4T by co-delivery of miR-142-3p 
mimics (data not shown). In monocytic U937 cells, however, 
luciferase expression was only observed after being trans-
fected with the luciferase encoding plasmid devoid of the 
miR 142-3p target sequences confirming APC de-targeted 
expression with these miR target sequences (Fig. 5b). When 
assessed in vivo in NIH Swiss mice, luciferase expression 
from pcLuc+miR4T/-NeoR again declined quickly with ki-
netics similar to the unmodified pcLuc+ plasmid (Figs. 5c). 
De-targeting luciferase expression from APCs significantly 
reduced anti-luciferase IgG levels (2.2x106pg/ml) compared 
to the control group (52 x106pg/ml) (p0.05) (Table 1, Fig. 
9b). 
 
Fig. (3). Luciferase immunogenicity in NIH Swiss mice. The 
plasmid pcLuc+/-NeoR (35 μg) encoding luciferase was delivered 
in Swiss mice by IM injection with EP and expression was visual-
ised by bioluminescent imaging between 7 and 28 days after deliv-
ery (n=9). Images are shown in (Fig. S1a) with the decline in lu-
ciferase activity shown in (a) as the fraction of remaining activity 
compared to the day 7 peak. At day 28 antibodies reactive to lu-
ciferase protein were detected by western blot (b). The samples are 
lysates of 293T cells transfected with 1-control plasmid pcDNA3; 2 
and 3 pcLuc+; and 4 a control transfection and probed with pooled 
sera (diluted 1:100) collected on day 28 from treated mice.  
 
The Effect of GAr Stabilisation on Duration of Trans-
gene Expression 
We have modified the synthetic tetracycline transactiva-
tor (rtTA2S-M2) [33] with GAr domains and demonstrated 
expression, retained activity and an increase in t1/2 by pulse 
chase experiments indicating at effect on protein stabilisation 
by the same GAr30 domain that was used to modify lu-
ciferase (Fig. S2). In a previous study luciferase was modi-
fied with the full length GAr domain from EBNA-1 with 
some loss of enzyme activity observed [26]. We cloned the 
GAr30 sequence and the full length EBNA-1 GAr into the 
luciferase reporter construct. When GAr modified versions 
of luciferase were expressed in vivo from the CMV promoter 
luciferase activity for the GAr30 molecule was expressed at 
a slightly higher level than the unmodified luciferase mole-
cule, whilst expression of the full length GAr molecule was 
significantly (p0.005) lower (Table 1, Fig. 9a). The dura-
tion of expression of GAr modified versions of luciferase in 
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mice was significantly reduced compared to the unmodified 
luciferase (Figs. 6a & b). The low level expression of GAr-
luciferase also resulted in a reduction in the level of anti-
luciferase antibodies in the sera (Table 1, Fig. 9b). 
 
 
Fig. (4). Effect of targeting luciferase expression to skeletal 
muscle. Plasmids pcLuc+/-NeoR and pc5-12Luc+/-NeoR were 
delivered to skeletal muscle by IM injection with EP (a) or to lung 
with JetPEI (b). Expression in the muscle of NIH Swiss mice was 
determined 7 days after DNA (35 μg) delivery and images are cap-
tured for 10 seconds at high resolution. For lung expression DNA 
(20 μg) complexed with JetPEI was delivered by i.v. injection in 
female Balb/c mice and luciferase expression was determined 24 
hours later with images captured for 5 minutes at high resolution. 
The muscle specific expression plasmid pc5-12-Luc+/-NeoR (35 
μg; n=7) was delivered to NIH Swiss mice and luciferase expres-
sion monitored by bioluminescent imaging. Weekly images are 
depicted in (c), whilst the decline in luciferase expression from the 
day 7 peak is shown in (d) as mean values +/- SEM (open triangles) 
and are plotted against the pcLuc+ controls (black squares).  
 
Fig. (5). The effect of de-targeting luciferase expression away 
from haematopoetic cells. Detection of the ubiquitous miR-16 and 
the haematopoetic selective miR-142-3p in cells lines by PCR am-
plification from the purified small RNA fraction (a). Expression of 
luciferase from pcLuc+, and versions with 2 and 4 target sequences 
for miR 142-3p in U937, C2C12 and 293T cells (b). Detection of 
luciferase expression by bioluminescent imaging on days 7 and 28 
after delivery of plasmid DNA pcLuc+/-NeoR or pcLuc+/4T/-NeoR 
with 4 miR target sequences for 142-3p (Fig. S1b). Images were 
captured for 10 seconds at high resolution. The decay of luciferase 
expression from the day 7 peak is illustrated for pcLuc+ (black 
squares) and pcLuc+/4T (open triangles; n=8) (c). Values in dia-
grams are the mean of at least triplicate readings and vertical bars 
are +/- SEM. 
 
Combined Muscle Specific Promoter and De-Targeted 
Expression from APC  
We then examined the combination of myotube expres-
sion and haematopoietic cell de-targeting using the c5-12 
promoter with miR 142-3p target sequence in the vector c5-
12-Luc+miR4T/-NeoR. We observed a significant increase 
in maintenance of luciferase expression at all time-points 
compared to the pcLuc+/-NeoR plasmid (Fig. 7). The kinet-
ics of luciferase expression decline are interesting because 
levels are maintained at near steady state up to day 14 (93% 
of day 7 peak), after which there is a decline, which at day 
28 is still 20% of the day 7 peak. This expression context 
also led to significantly (p0.05) reduced anti-luciferase IgG 
levels compared to the unmodified expression vector group 
(Table 1, Fig. 9b). 
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Fig. (6). The effect of GAr modification on the duration of luciferase expression. Bioluminescent imaging of mice that received plasmid 
pcLuc+/GAr30/-NeoR (captured for 1 second; n=5) and pcLuc+/GAr/-NeoR (captured for 10 minutes; n=5) are shown in Fig. S3a whilst the 
relative decay in the luciferase signal in these groups is compared to the day 7 peak illustrated in a and b, respectively. Values are the mean 
+/- SEM and significant differences between the pcLuc+ group (black squares) and the GAr modified groups (white symbols) of p0.05 are 
indicated by . 
 
 
Fig. (7). Combined muscle targeting and APC de-targeting on 
duration of luciferase expression. Mice were delivered the plasmid 
c5-12Luc+/-NeoR/4T (n=9) and luciferase activity was determined 
by bioluminescent imaging at time points between day 7 to day 28. 
Bioluminescent images are depicted in Fig. S3b. The averaged data 
for the group (open triangles) shows the decay in luciferase activity 
compared to the day 7 peak and is plotted along with the pcLuc+ 
group (black squares). Significant differences between the pcLuc+/-
NeoR group and the c5-12Luc+/4T/-NeoR group of p0.005 and 
p0.05 are indicated by  and , respectively. 
 
A Combination of miR Sequences and Promoter Target-
ing of GAr Modified Luciferase 
When expression of GAr30 luciferase was de-targeted 
from haematopoietic cells with the miR 142-3p target se-
quences, the initial decline in expression was as rapid as un-
modified luciferase, the rate of decline then slowed signifi-
cantly by day 21 (p0.005 and was almost statistically sig-
nificant at day 28 p=0.056) (Fig. 8a) reflecting the signifi-
cantly (p0.05) reduced anti-luciferase IgG levels in these 
mice (Table 1, Fig. 9b). When expression of GAr30 lu-
ciferase was targeted to myocytes with the c5-12 promoter, 
the kinetics of the decline in luciferase activity was compa-
rable to that seen with unmodified luciferase (Fig. 8b). Inter-
estingly, combining the muscle specific promoter and APC 
de-targeting, GAr30 luciferase expression was significantly 
enhanced at day 14 compared to expression from pcLuc+/-
NeoR (Fig. 8c). When the same targeting and de-targeting 
strategies were employed with luciferase containing the full 
length GAr there were increased levels of luciferase activity 
and reduced levels of anti-luciferase IgG compared to ex-
pression from the CMV promoter (Table 1), but luciferase 
expression levels were still rapidly reduced (Fig. S5).  
Relationship Between Luciferase Expression Profile and 
the Immune Response 
Real time imaging provides a read out of luciferase ex-
pression at several time-points in the same mouse which 
means that the expression profile over the course of the ex-
periment for each mouse can then be related to the anti-
luciferase IgG measured in day 28 serum. In Fig. (9a) we can 
see that the expression profile of luciferase expressed as 
AUC is significantly reduced from all vectors where the full 
length GAr is fused to the luciferase protein. The only other 
group where the kinetics of luciferase expression are signifi-
cantly reduced are those treated with the vector pcLuc+/-
NeoR/4T which should prevent expression of luciferase in 
APCs (Fig. 9a). When anti-luciferase IgG levels are meas-
ured they are significantly reduced in all groups compared to 
the pcLuc+/-NeoR control with the exception of groups 
where GAr30 modified luciferase is expressed without miR 
de-targeting from APCs (Fig. 9b). Because expression level 
influences the immune response we can normalise antibody 
levels with expression levels by simple division as illustrated 
in Fig. 9c. The data clearly show that despite the lower ex-
pression of full length GAr modified luciferase from the con-
stitutive CMV promoter the relative immune response that 
develops is greater than observed with the control vector 
pcLuc+/-NeoR (Fig. 9c). Similarly, T cell stimulation studies 
(Fig. S6) suggest that IL-2 production in response to lu-
ciferase protein stimulation is also elevated (Fig. S6C) rela-
tive to the level of luciferase expression. By contrast, most 
vectors in which luciferase expression was de-targeted from 
APCs with miR 142-3p target sequences displayed a reduced 
humoral immune response (Fig. 9c) confirming that this 
strategy can reduce immunogenicity of foreign transgenes 
expressed in the correct context. 
Strategies to Prolong Foreign Transgene Expression Current Gene Therapy, 2015, Vol. 15, No. 1    11 
 
Fig. (8). The effect of APC de-targeting and muscle targeting on 
duration of GAr30-luciferase expression. In the plasmid 
pcLuc+/GAr30/4T/-NeoR, GAr30 modification and miR 142-3p 
de-targeting are combined. Bioluminescent images of NIH Swiss 
mice are shown in Fig. (S4) whilst graphs of averaged data for the 
decrease in expression from the day 7 peak for pcLuc+/GAr30/4T/-
NeoR is shown (a). When expression of the same GAr 30 modified 
luciferase was targeted to skeletal muscle with c5-12 promoter from 
the plasmid c5-12Luc+/GAr30/-NeoR the expression data is illus-
trated (b). When the muscle promoter and miR de-targeting are 
combined averaged data is shown in (c). Significant differences 
from the decline in luciferase expression from pcLuc+/-NeoR 
(black squares) of p0.005 are indicated by (n=5 for each group). 
 
Fig. (9). Anti-luciferase IgG levels relative to luciferase expres-
sion levels. Total luciferase expression during the 28 day experi-
ment was calculated as AUC (a) and anti-luciferase IgG in sera 
collected at day 28 were determined by Elisa (b) levels of anti-
luciferase IgG relative to luciferase expression levels are shown in 
(c). Significant differences of p<0.05 and p<0.005 from the 
pcLuc+/-NeoR group are indicated by  and , respectively.  
 
DISCUSSION AND CONCLUSION 
The method of gene delivery is an important factor af-
fecting immune responses to expressed transgenes. Plasmid 
DNA contains CpG motifs that are immunostimulatory, act-
ing through TLR9, and cytoplasmic dsDNA also triggers 
IFN production through intracellular sensors such as DAI 
(DNA-dependent activator of IFN-regulatory factors) [34] 
and AIM2 (absent in melanoma 2) [35]. In addition, delivery 
methods for plasmid DNA typically cause some tissue dam-
age so there is also interaction with the immune system via 
clearance of cell debris [36]. These attributes of plasmid 
gene expression has led to the development of DNA vaccina-
tion, which is also enhanced by EP [37] and is being actively 
pursued for clinical application [38, 39]. Firefly luciferase is 
a foreign protein in mice yet it has been expressed long-term 
in some inbred strains without sign of immune rejection [6]. 
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Wolff et al., [28] reported that luciferase is immunogenic in 
outbred ICR mice. We also observed luciferase immuno-
genicity in outbred ICR mice (data not shown) and in out-
bred NIH Swiss mice following plasmid delivery to skeletal 
muscle by injection and EP with the formation of reactive 
antibodies and T cell responsiveness in vitro to exogenous 
luciferase. Through the use of bioluminescent imaging we 
were able to observe the decline in luciferase activity in real-
time and over a period of 28 days we consistently saw that 
activity decreased by approximately 95% from the peak level 
at day 7. This imaging technology gives us a unique ap-
proach to follow the reduction in luciferase expression and to 
readily examine strategies to prolong the duration of lu-
ciferase expression. Clearly, both the innate and adaptive 
immune systems have the potential to affect luciferase ex-
pression along with tissue remodeling and promoter silenc-
ing. Experiments in SCID mice give an insight of the contri-
bution of all these components to the reduction of luciferase 
expression with the exception of the adaptive immune sys-
tem. In these mice we see that luciferase activity is rapidly 
reduced between day 7 and 14 to approximately 50% where 
it then stabilises until day 28. In this study we were inter-
ested in counteracting the adaptive immune response that 
accounts for the additional elimination of the foreign trans-
gene we observed in outbred mice. 
The strategies we have employed target different aspects 
of the immune response. Directing expression to myocytes 
through the use of the c5-12 promoter did not alter the dura-
tion of luciferase expression compared with using the ubiqui-
tous CMV promoter. The amount of expressed foreign pro-
tein is an important factor in the induction of immune re-
sponses, and we confirm here that the synthetic c5-12 pro-
moter is of similar strength to the CMV promoter. Use of a 
weaker promoter and hence lower levels of expressed for-
eign protein contributes to evasion of the immune system. 
This is illustrated with luciferase immunogenicity in ICR 
mice following hydrodynamic plasmid delivery to muscle 
which showed that expression persisted at 50% of maximum 
after 2 months when expressed with the MCK promoter 
which was 35 times weaker than the CMV promoter after 7 
days in this study [28]. 
By de-targeting luciferase expression from APCs with 
miR 142-3p, CD8 priming from endogenous antigen via 
MHC Class I should be prevented and B cell activation via 
MHC Class II should also be reduced. Indeed we observed 
reduced antibody production when 142-3p sequences were 
used in most constructs, however, this strategy alone did not 
alter the duration of luciferase expression in Swiss mice. 
This is not too surprising as the main inducer of the immune 
response is thought to be Ag expressed in non-lymphoid 
tissues that is transferred to APCs [40]. But combined de-
targeting with myotube specific expression did reduce the 
anti-luciferase IgG levels and significantly prolonged the 
duration of luciferase expression, with luciferase activity 
falling by 80% after 28 days. When Wolff et al. [28] de-
targeted plasmid expression of luciferase in skeletal muscle 
of ICR mice with the same miR sequences and the MCK 
promoter they did not see any change in the luciferase rejec-
tion compared with the MCK promoter alone, partly because 
the weaker MCK promoter significantly reduced immuno-
genicity on its own. In both studies luciferase remained im-
munogenic (both decline in expression and antibody forma-
tion) suggesting that foreign transgene expressed from plas-
mid DNA in skeletal muscle cannot be completely prevented 
by this de-targeting strategy in contrast to observations with 
lentivirus expression of EGFP in the liver [18]. Further re-
search is necessary to establish the exact reason for this dis-
crepancy which may be related to the mouse strain (outbred 
vs. Balb/c), target tissue (skeletal muscle vs. liver), delivery 
vector (plasmid vs. lentivirus) or foreign transgene (lu-
ciferase vs. EGFP). Indeed the complexity of the issue was 
highlighted in a recent study where immunogenicity of 
AAV1 expressed human sacroglycan protein could be pre-
vented in C57Bl/6 mice using 142-3p sequences alone, but 
rejection was only delayed in sacroglycan-deficient dys-
trophic mice [41]. However, the inflammatory state of the 
muscle at the time of gene delivery will also differ between 
these mice.  
The full length GAr domain from EBNA-1 should pre-
vent processing for MHC Class I presentation of expressed 
transgene which has been previously demonstrated in in vitro 
studies [26, 42]. This effect should prevent the MHC Class I 
presentation route in transfected APCs and also prevent the 
MHC Class I presentation in myocytes which targets them 
for destruction by cytotoxic T cells. The long GAr domain 
will not, however, prevent CD8 priming following cross-
presentation [26]. 
When we used the full length GAr domain from EBNA-
1, we observed reduced levels of luciferase expression and a 
rapid decline in luciferase expression compared with expres-
sion of unmodified luciferase. Furthermore, the duration of 
expression of the full length GAr modified luciferase was 
unaltered by combinations of targeting and/or de-targeting. 
These observations contrast with use of the full length GAr 
domain for maintenance of LacZ transgene delivered with 
adenovirus in Balb/c skeletal muscle where expression per-
sisted for 19 days, but was only detected in 1 of 4 mice de-
livered the unmodified LacZ [26]. An important difference is 
the more stringent immune response observed in the outbred 
mice that we have utilised in our study. 
Fusing the small GAr30 sequence (which we show in-
creased the t1/2 of rtTA-2SM2) to luciferase increased the 
level of luciferase expression in vitro and in vivo suggesting 
a similar stabilisation, but still did not affect the elimination 
rate of luciferase expression. Although, de-targeting expres-
sion from APCs with miR 142-3p target sequences did sig-
nificantly slow the reduction in luciferase activity which may 
be due to reduced MHC class I presentation so evading 
clearance of transfected cells by CTLs. When GAr30 modi-
fied luciferase was also targeted to myoblasts there was a 
further improvement in the duration of luciferase activity, 
but not better than when the same strategy was employed 
with unmodified luciferase.  
Whilst this study has not unlocked a strategy to achieve 
persistent foreign transgene expression the de-targeting ap-
proach was shown to prolong luciferase expression and GAr 
30 modification did display some improvement when ex-
pression was de-targeted from APCs. Plasmid DNA is not 
itself immunogenic, but it does trigger several intra-cellular 
sensors (TLR9, DAI, AIM-2) and physical delivery tech-
niques combine to provide a strong ’danger’ signal to the 
Strategies to Prolong Foreign Transgene Expression Current Gene Therapy, 2015, Vol. 15, No. 1    13 
immune system. Delivery methods that do not stimulate the 
immune system could potentially dampen this signal and 
permit more subtle gene delivery. This study has also shown 
that luciferase has advantages as a foreign transgene for 
monitoring duration of expression in vivo because of the 
ability to repeatedly perform real-time measurements. 
Greater analysis of the immune response could be achieved 
if immunodominant epitopes of luciferase were character-
ised, reactive T cell clones were available, and there was a 
better understanding of the relative contributions of direct 
and cross-priming to the immune response.  
LIST OF ABBREVIATIONS 
Ag = Antigen 
APC = Antigen presenting cell 
CMV = Cytomegalovirus 
CTL = Cytotoxic T lymphocyte 
EBNA = Epstein-barr nuclear antigen 
EGFP = Enhanced green fluorescent protein 
EP = Electroporation 
GAr = Glycine-alanine repeats 
HRP = Horseradish peroxidase 
MHC = Major histocompatibility complex 
miR = microRNA 
NK = Natural killer 
PBS = Phosphate buffered saline 
UTR = Untranslated region 
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